MG-132

MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

Price Stock Quantity  
USD 100 In stock
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MG-132 Chemical Structure

MG-132 Chemical Structure
Molecular Weight: 475.62

Validation & Quality Control

Product Use Citation(42)

Customer Product Validation(9)

Quality Control & MSDS

Related Compound Libraries

MG-132 is available in the following compound libraries:

Proteasome Inhibitors with Unique Features

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.
Targets Proteasome [1]
(Cell-free assay)
IC50 100 nM
In vitro MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LPS-stimulated RAW264.7 cellsNVTCcWd7TnWwY4Tpc44hSXO|YYm=MnzWNlUh|ryPMWfEUXNQNY\zZXlkUW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMTFOwG0>NFjmVoozPDZ7N{S5Oi=>
HL-60M3jG[mN6fG:2b4jpZ{BCe3OjeR?=NXzXSYM1PDBizszNNXTkNpd7PDhiaB?=NVHpXWo{TE2VTx?=M1PTSWlEPTB:MUCg{txOMoDINlQ3QTd2OU[=
SMMC-7721NH7rboVEgXSxdH;4bYMhSXO|YYm=NHr2e4I1OCEQvF2=M2TDXlQ5KGh?MmKxSG1UVw>?M2qyNmlEPTB;Nz6xJO69VQ>?MoHGNlQ3QTd2OU[=
A-549M{D5W2N6fG:2b4jpZ{BCe3OjeR?=MV60NEDPxE1?NEOwZpg1QCCqMnjYSG1UVw>?Mn;FTWM2ODxzMDFOwG0>NHvHXYQzPDZ7N{S5Oi=>
MCF-7NWX1NZdYS3m2b4TvfIlkKEG|c3H5MVW0NEDPxE1?NFrzelQ1QCCqM{PrN2ROW09?NIfz[XBKSzVyPUeuN{DPxE1?NHTnZYozPDZ7N{S5Oi=>
SW-480MX;DfZRwfG:6aXOgRZN{[Xl?M{nkb|QxKM7:TR?=MYK0PEBpNYLic|VITE2VTx?=NGH1WoJKSzVyPUSg{txOMVqyOFY6PzR7Nh?=
NCI-H929NWnhTI1KS3m2b4TvfIlkKEG|c3H5M17RPVEh|ryPNEOyXYg4OiCqNH72XZJFVVORMkLpTWM2OD1yLkG3JO69VQ>?MXGyOFYzPTB6OB?=
293TNUnubpY6S3m2b4TvfIlkKEG|c3H5MUixNEDPxE1?M4jQfFczKGh?M2C5U2ROW09?M13odmlEPTB:MjFOwG0>NUnQfVZ7OjR4MkWwPFg>
293TMluxSpVv[3Srb36gRZN{[Xl?NUD4cY8xOTBizszNMVOyOEBpM331[2ROW09?MkH2UY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>?M3\VZlI1PjJ3MEi4
HeLaNELvN2JMcW6jc3WgRZN{[Xl?NH3HNmgyOCEQvF2=MYGxJIg>MXvEUXNQM2XnbWlv\HWlZYOgVGFTWCClbHXheoFo\SCkeTDpcohq[mm2aX7nJJBzd3OnYYPvcYUh[WO2aY\peJk>MYGyOFMzOTh|Mx?=
MDA-MB-231M3PqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\XTnIyKM7:TR?=MkGxO|IhcA>?NIG1UGFFVVORMYXJR|UxRTBwMUig{txONHO1N5ozPDF3M{KwOi=>
MCF-7M1\LOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUOxJO69VQ>?M3HuUlczKGh?NFPTXZdFVVORMkW4TWM2OD1yLkGzJO69VQ>?MWKyOFE2OzJyNh?=
MCF10AMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUWxJO69VQ>?NEfQVlU4OiCqMn\oSG1UVw>?MWfJR|UxRTBwMkmg{txONVjFWmNVOjRzNUOyNFY>
HEK-293MmTyT4lv[XOnIFHzd4F6M{LCVlIh[W6mIEKwJO69VQ>?M1nDc|IhcA>?NY\kN4t4TE2VTx?=MUjJcohq[mm2czDDbHQuVCCjY4Tpeol1gSC5aYToJGlEPTBib3[gPUBvVSB?NF3YVVAzOzV2MEe5NC=>
Calu6NHfkU2JHfW6ldHnvckBCe3OjeR?=MofMNVAh|ryPNXj1Vlc4OThiaB?=MWrEUXNQMW\TbYdvcW[rY3HueIx6KGGlY4XteYxifGW|IH\yZZRigGmwIIDy[YN2enOxch?=MYKyN|UxPjR6Nh?=
IFN-gamma-induced RAW264.7MUnGeY5kfGmxbjDBd5NigQ>?NX60VlR4TE2VTx?=MVnJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszNM4LNVFIzOjd5Mke3
IPC227FNYjS[llrS3m2b4TvfIlkKEG|c3H5NGHmZoYyKM7:TR?=MlXnOFghcA>?MnK5SG1UVw>?M3nWeGlEPTB;MD6wO|ch|ryPNGjVcFczOTl{NEWyPC=>
Hepa-1c1c7MVPGeY5kfGmxbjDBd5NigQ>?MUKyOUDPxE1?M{TGXlYhcA>?MlfaSG1UVw>?M3TjOGlv[3KnYYPld{BPemZ{IIDyc5RmcW5ibHX2[Yw>NIL0SY8zODN7MkW0OC=>
COS-7MWjDfZRwfG:6aXOgRZN{[Xl?MmrUNVAh|ryPM3SzXmROW09?M1\HOGlEPTB:MUCg{txONIexZWYyQDB6OEC5Oy=>
HuH-7MVXDfZRwfG:6aXOgRZN{[Xl?MUKxNEDPxE1?NEHiXnlFVVORM2\GTmlEPTB:MUCg{txONHzHbmsyQDB6OEC5Oy=>
OCI-Ly3NFfIenhHfW6ldHnvckBCe3OjeR?=MmjNNVAh|ryPwrC=NEP6Rm41KGh?NHy3eI5FVVORMVnJcoR2[2W|IHj1cYFvKEmtYYDwZWJidHCqYTDzeIFjcWyrenH0bY9vKHerdHigSWM2OCCxZjCxJO69VQ>?M4nq[VE5ODJ2MUGz
A2780 cDDPM3PSPGFxd3C2b4Ppd{BCe3OjeR?=NUX6PWVmOjRiaB?=MUjEUXNQNVeySnFwUW6mdXPld{BieG:ydH;zbZMh[nliaX7obYJqfGmwZzDQWGVPKGSnZ4Lh[IF1cW:wM{D3OFE4Pjh2MEG4
LPS-stimulated RAW264.7 cellsMVXGeY5kfGmxbjDBd5NigQ>?NV\ie2N3TE2VTx?=MXHJcohq[mm2czDOSk1s[XCyYVKgSG5CKGKrbnTpcoc>NE\CdmoyPzRyN{K3Oy=>
PC12M{LJWGZ2dmO2aX;uJGF{e2G7M3:yTlExOCEQvF5CpC=>MoD4NlQhcA>?M1rLNGROW09?MmrlTY5pcWKrdIOgOk1QUESDLTDhcoQhUDKRMj3pcoR2[2WmIHP5eI91d3irY3n0fS=>NUWzXZo5OTdzNUi0OVQ>
PC3MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnZfGNvOjBizszNNILNcWs1QCCqMWTEUXNQNID3UIpKSzVyPUCuOkDPxE1?MnXuNVY3QDZ3M{e=
LP-1MV7BdI9xfG:|aYOgRZN{[Xl?NXfV[oZQOzByIH7NMnvaNlQhcA>?M1vlXWROW09?MXjJcoR2[2W|IHHwc5B1d3OrczDifUBqdmO{ZXHzbY5oKGOuZXH2[YQhWEGUUDDs[ZZmdCCjbnSgdoVlfWOrbnegUYNtNTFicILveIVqdiCuZY\lcC=>NYC0WIEzOTV7NUi1PFk>
ES6MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mke3TWM2OD1yLkCxN|A3KM7:TR?=MYrTRW5ITVJ?
A101DNITXOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfMTWM2OD1yLkCzNlc6KM7:TR?=MYjTRW5ITVJ?
OCUB-MMk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn21TWM2OD1yLkCzO|M4KM7:TR?=M2nQd3NCVkeHUh?=
LB2518-MELMlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETOXHRKSzVyPUCuNFM4PiEQvF2=MWjTRW5ITVJ?
SH-4NYTjT2lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXTOnNKSzVyPUCuNFQ{OSEQvF2=Mon5V2FPT0WU
KNS-42NHXSSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NICzWoVKSzVyPUCuNFQ1PDFizszNMmLkV2FPT0WU
DSH1MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zuVGlEPTB;MD6wOVI5QSEQvF2=M1TvWHNCVkeHUh?=
NTERA-S-cl-D1MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUH4O|RtUUN3ME2wMlA2Pzd{IN88US=>NWX2UmVZW0GQR1XS
D-542MGMlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTH[VdnUUN3ME2wMlA2QTV5IN88US=>NHvzW3pUSU6JRWK=
KS-1NGDJNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjOTWM2OD1yLkC2OFU5KM7:TR?=NGrDUIZUSU6JRWK=
BL-41MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEf5bWJKSzVyPUCuNFY6PDdizszNNEKwWItUSU6JRWK=
LXF-289M1rnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTBwMEewOlYh|ryPNHLnW5RUSU6JRWK=
D-247MGNX3uOFM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXNW|NKSzVyPUCuNFczODlizszNMlPPV2FPT0WU
MMAC-SFMorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3TRoZKSzVyPUCuNFczPjhizszNMVLTRW5ITVJ?
CP66-MELNHO1U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWP1eWliUUN3ME2wMlA4PSEQvF2=M1;oO3NCVkeHUh?=
LB771-HNCNF;WW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlL2TWM2OD1yLkC4NFM3KM7:TR?=MnXKV2FPT0WU
no-10MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVG5dmVSUUN3ME2wMlA5QTB7IN88US=>M1zsTHNCVkeHUh?=
A388MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGL4SFJKSzVyPUCuNFkxPjVizszNM4DBVXNCVkeHUh?=
OPM-2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrFTWM2OD1yLkGwOFc1KM7:TR?=MXLTRW5ITVJ?
OVCAR-4M1XXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTBwMUC5N|gh|ryPNH\2WYZUSU6JRWK=
HOP-62NFjXZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTUdlFKSzVyPUCuNVA6PDlizszNMoHBV2FPT0WU
ML-2NV;oOlFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTCdpVKSzVyPUCuNVE5ODZizszNNXrJWXJUW0GQR1XS
UACC-257NHvifpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTBwMUG5Nlch|ryPMXLTRW5ITVJ?
NEC8MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLhXJJKSzVyPUCuNVE6QTVizszNNEeyXIdUSU6JRWK=
ONS-76M1m0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4X2N2lEPTB;MD6xNlk{PSEQvF2=M{PhSnNCVkeHUh?=
KE-37M4nmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULnUZFUUUN3ME2wMlE{Ojd6IN88US=>MYnTRW5ITVJ?
HT-144MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTBwMUO4PVUh|ryPNWr3eVFpW0GQR1XS
LB2241-RCCNWXEXG1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrzZWFmUUN3ME2wMlE1OjR5IN88US=>MojqV2FPT0WU
TE-5MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTBwMUSyO|gh|ryPNIHPcZRUSU6JRWK=
KINGS-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvDRldKSzVyPUCuNVQ4QSEQvF2=Mmf4V2FPT0WU
NCI-H69NHLmV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHz4SG5KSzVyPUCuNVUyPDFizszNNVHaZ25bW0GQR1XS
CAS-1NXHHcJNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTBwMUW0PFIh|ryPNUPpU3l4W0GQR1XS
D-263MGNYe2S2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnR[YFTUUN3ME2wMlE3ODB4IN88US=>MnPMV2FPT0WU
A253M{\rfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfFc2RKSzVyPUCuNVYyOjhizszNNHGwcI9USU6JRWK=
PF-382NXe5SoxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHRTWM2OD1yLkG2O|A3KM7:TR?=M12z[XNCVkeHUh?=
CESSMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPGTWM2OD1yLkG3NFYh|ryPMY\TRW5ITVJ?
MZ2-MELMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTvWYhKSzVyPUCuNVc2PTlizszNMnXaV2FPT0WU
HELMmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3f2XWlEPTB;MD6xPFUyPyEQvF2=NFLBeXdUSU6JRWK=
D-392MGNHe1Wm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7CRZBlUUN3ME2wMlE6OTF3IN88US=>NEXw[2FUSU6JRWK=
SK-LMS-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zmbGlEPTB;MD6xPVMxOyEQvF2=Mmi4V2FPT0WU
GI-ME-NNULFTZAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3H[IJKSzVyPUCuNVk{ODZizszNMkTMV2FPT0WU
LB831-BLCMoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jCTGlEPTB;MD6xPVM1KM7:TR?=MUfTRW5ITVJ?
DU-4475NI[3UGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnHTWM2OD1yLkG5OlU5KM7:TR?=NYf6eYVyW0GQR1XS
IST-SL1NInSdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwMkCwPVQh|ryPMkLSV2FPT0WU
GAKNHfYOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIj6bmJKSzVyPUCuNlA2OzRizszNNYfmeJpyW0GQR1XS
EW-1NUPLW2tlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDTTWM2OD1yLkKxNFQ4KM7:TR?=MXnTRW5ITVJ?
LAMA-84MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M36ydWlEPTB;MD6yNVg2OSEQvF2=NWDlXoR3W0GQR1XS
SK-UT-1MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF32RnFKSzVyPUCuNlIxPDlizszNMnzRV2FPT0WU
VA-ES-BJNHrkV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TlUGlEPTB;MD6yNlI2PyEQvF2=MYrTRW5ITVJ?
ACNMmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLkTWM2OD1yLkKyOlM5KM7:TR?=MULTRW5ITVJ?
SK-PN-DWNHG5TmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGr5ZY5KSzVyPUCuNlMyQSEQvF2=NWPYU5hkW0GQR1XS
HD-MY-ZNVrPSndDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjPZ4JKSzVyPUCuNlM{ODNizszNNVW3SpJVW0GQR1XS
LB373-MEL-DNFu3eZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTCNHBKSzVyPUCuNlQyQThizszNNHrOXldUSU6JRWK=
COLO-829NXO3[m9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLzTWM2OD1yLkK0NlU4KM7:TR?=M2Pu[nNCVkeHUh?=
ES8NE\ZWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTBwMkS3OlMh|ryPMWfTRW5ITVJ?
RXF393MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn71TWM2OD1yLkK1NFE2KM7:TR?=NF6xRZNUSU6JRWK=
TK10NGjXb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIK4b3lKSzVyPUCuNlU1OzVizszNM4LKUXNCVkeHUh?=
LOUCYNYf5fGJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2WxNmlEPTB;MD6yOVQ2PiEQvF2=MmrWV2FPT0WU
MZ7-melM4TFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3MPFdOUUN3ME2wMlI3Ozd2IN88US=>NEPTdXlUSU6JRWK=
CP67-MELNUXnTpZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTBwMk[3N{DPxE1?MVfTRW5ITVJ?
C2BBe1NVrxeoxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTBwMke5NFch|ryPMXXTRW5ITVJ?
K052MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjNVI9KSzVyPUCuNlg6QSEQvF2=NXr1NWtoW0GQR1XS
MOLT-16M13DR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfueWFKSzVyPUCuNlk2OjRizszNM1juWnNCVkeHUh?=
KNS-81-FDNFm1cXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;LTWM2OD1yLkOwN|I{KM7:TR?=NWG4[VdMW0GQR1XS
CMKNVjMSIdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nSNWlEPTB;MD6zNVEzKM7:TR?=M3LVOXNCVkeHUh?=
LAN-6MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7JWGVPUUN3ME2wMlMyOyEQvF2=MVrTRW5ITVJ?
KLEMlzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfj[otPUUN3ME2wMlMyOzB4IN88US=>NIPuNHFUSU6JRWK=
NCCITNHr5e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1X4TGlEPTB;MD6zNVc5OyEQvF2=NGPZZmVUSU6JRWK=
HHMlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHVTWM2OD1yLkOyPFk4KM7:TR?=NGfuboFUSU6JRWK=
TE-8MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXL1V4JZUUN3ME2wMlM1Ojd7IN88US=>NWnndHc6W0GQR1XS
GDM-1NEm2eIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2G4SmlEPTB;MD6zOVExPCEQvF2=NEfNVpNUSU6JRWK=
NCI-H747NYrnOFRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\KTWM2OD1yLkO3NVA{KM7:TR?=MXzTRW5ITVJ?
NCI-H1092Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\XTWM2OD1yLkO4PFQ1KM7:TR?=Mn;jV2FPT0WU
8-MG-BAM4W4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLSTWM2OD1yLkO5PFM4KM7:TR?=M3WzeHNCVkeHUh?=
NB17MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXiUIJ3UUN3ME2wMlQzQTdizszNMo\BV2FPT0WU
LC4-1M1;Mb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnW4TWM2OD1yLkSzOlA4KM7:TR?=MU\TRW5ITVJ?
TE-1NXHJelhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HLe2lEPTB;MD60OVEyQSEQvF2=M{TvbXNCVkeHUh?=
KALS-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\rb2lEPTB;MD60OlU5PCEQvF2=NHvNfZNUSU6JRWK=
CCRF-CEMNXmyRnBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTOc5dsUUN3ME2wMlQ4Pjd2IN88US=>MkG5V2FPT0WU
OS-RC-2NV\MdnhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTBwNEe5O|Ih|ryPMYPTRW5ITVJ?
A704M3WwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHOWYZKUUN3ME2wMlQ5Pjl{IN88US=>NV\ybJlwW0GQR1XS
BB49-HNCNWLZ[2t5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\LflRNUUN3ME2wMlQ6ODl4IN88US=>Mkn4V2FPT0WU
EVSA-TMnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PJPWlEPTB;MD60PVkyOSEQvF2=NV:zXFRSW0GQR1XS
Mo-TNXLWbXo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXCbZlKSzVyPUCuOVE4PjJizszNM2\UNnNCVkeHUh?=
MONO-MAC-6M3viUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTaSVJOUUN3ME2wMlU{PjFzIN88US=>MXvTRW5ITVJ?
BB65-RCCM{nyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vmUGlEPTB;MD61OlgyOSEQvF2=NYHkbFNPW0GQR1XS
NCI-H1882MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3VT|lnUUN3ME2wMlU6ODN4IN88US=>M4m0NXNCVkeHUh?=
TE-9NYj4ToVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfWUGZKSzVyPUCuOlExOzNizszNMmnBV2FPT0WU
NCI-H2126NX;YbHNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7EZnpXUUN3ME2wMlYzPjZ7IN88US=>MYTTRW5ITVJ?
SF268MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1;3N2lEPTB;MD62OVY1OSEQvF2=M2jueXNCVkeHUh?=
SW872MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn65TWM2OD1yLk[1O|I6KM7:TR?=NWPR[YZQW0GQR1XS
LS-513MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3W3bGlEPTB;MD62Olc2OSEQvF2=MlHBV2FPT0WU
NCI-H1355M4G2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTYUWEzUUN3ME2wMlY5PjF7IN88US=>NYHHelE3W0GQR1XS
BL-70MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVKxWoxKUUN3ME2wMlY6Ozh6IN88US=>NYfJNFdtW0GQR1XS
NCI-SNU-5NFH4SmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LDbWlEPTB;MD62PVU1PSEQvF2=MXLTRW5ITVJ?
SNU-C2BNYfLeYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDLTWM2OD1yLkewO|M6KM7:TR?=NHexXXdUSU6JRWK=
GB-1M3;Oemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jhTGlEPTB;MD63NlEzPCEQvF2=Mo\lV2FPT0WU
CTB-1NVf1OllrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIm5TWRKSzVyPUCuO|c6PTVizszNM2TWdHNCVkeHUh?=
BeckerNHfPOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwN{m2NlEh|ryPMWnTRW5ITVJ?
KM12NV7TT2FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrpZWRKSzVyPUCuPFU1PjZizszNNV3ZS|dMW0GQR1XS
ES7NHjWVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jlSmlEPTB;MD64PVY2KM7:TR?=MnrmV2FPT0WU
COLO-684MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1POemlEPTB;MD65NFY2QCEQvF2=NGjudZZUSU6JRWK=
HCC2998M4W5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jMV2lEPTB;MD65N|g2PCEQvF2=M{HV[nNCVkeHUh?=
TE-10MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PvV2lEPTB;MD65OlQ{KM7:TR?=MmC1V2FPT0WU
SF126M{D0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zl[2lEPTB;MD65PFk4OSEQvF2=NH3yc|JUSU6JRWK=
EKVXNWTCT4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LaR2lEPTB;MT6wN|Q1OiEQvF2=MUXTRW5ITVJ?
KARPAS-45MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXk[WNtUUN3ME2xMlA1ODF4IN88US=>NGfjZmtUSU6JRWK=
KGNMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjEfYVVUUN3ME2xMlA2ODR3IN88US=>MYTTRW5ITVJ?
ES1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPZTWM2OD1zLkC3PVIyKM7:TR?=NVXzdo1JW0GQR1XS
L-540NGHIcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoG2TWM2OD1zLkGxPFM6KM7:TR?=MVnTRW5ITVJ?
KURAMOCHIM3jQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTFwMUKzO|Qh|ryPNF;EfWtUSU6JRWK=
LU-65M2\abGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vPRmlEPTB;MT6xNlc2OyEQvF2=NGe3N4pUSU6JRWK=
MFH-inoMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojsTWM2OD1zLkG3OVAyKM7:TR?=NVjOfJBnW0GQR1XS
NCI-H23Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnWTWM2OD1zLkKwOFEh|ryPMnzoV2FPT0WU
IA-LMM33mRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV25ZWFCUUN3ME2xMlI1OTF4IN88US=>NWrwd|ZxW0GQR1XS
PSN1M2PEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkK1TWM2OD1zLkK3NFE3KM7:TR?=NVfFWoFWW0GQR1XS
NCI-H719NH2zcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXv3c3V6UUN3ME2xMlI4PDFzIN88US=>MXnTRW5ITVJ?
SW684MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHPTWM2OD1zLkK4OlU6KM7:TR?=NFWzO2lUSU6JRWK=
HCE-4M3vwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mor6TWM2OD1zLkOwNlIyKM7:TR?=NVHRTIEzW0GQR1XS
EW-16NXX1Z29ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnwemJSUUN3ME2xMlMyOzR5IN88US=>M2\JT3NCVkeHUh?=
NCI-H128NHfxSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\ad2lEPTB;MT6zOVgyPCEQvF2=M{ewcHNCVkeHUh?=
HC-1NGG4[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LKXmlEPTB;MT6zPFE4KM7:TR?=MnzkV2FPT0WU
IST-MES1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHod4ZHUUN3ME2xMlQxOjB6IN88US=>NIGzUmhUSU6JRWK=
RajiMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEmwdXdKSzVyPUGuOFE5PSEQvF2=MnK3V2FPT0WU
DMS-114NFLnNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHroc|dKSzVyPUGuOFQ2OzlizszNMkT1V2FPT0WU
GI-1NIfadXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLlTWM2OD1zLkS3NVMyKM7:TR?=MVfTRW5ITVJ?
NCI-H2081M1;6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHScm5KSzVyPUGuOVUyQTZizszNNIPyZY9USU6JRWK=
LC-1FM1ezfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7rTWM2OD1zLkW1NVk5KM7:TR?=NYDIR2tNW0GQR1XS
NCI-H2227MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTzWJVMUUN3ME2xMlYyPTZzIN88US=>M{\XPXNCVkeHUh?=
D-502MGNXnBfnZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTFwNkeyNVEh|ryPM4jCWnNCVkeHUh?=
NCI-H2141NYPD[m5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInyVHVKSzVyPUGuOlc{OTdizszNNEXIO2hUSU6JRWK=
LS-411NMnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTGTWM2OD1zLk[5PFA4KM7:TR?=NV;MZYNoW0GQR1XS
SU-DHL-1NWCybotKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3NeZhKSzVyPUGuO|EzQDFizszNM3nje3NCVkeHUh?=
BB30-HNCNITVNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jCPWlEPTB;MT63NlY5PSEQvF2=MoTmV2FPT0WU
TE-15NVz0dGZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DKfWlEPTB;MT65NlM4OyEQvF2=NHTTW3hUSU6JRWK=
JVM-3MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPFRmtSUUN3ME2xMlk{QTB2IN88US=>NIDrSGxUSU6JRWK=
IST-SL2NHHKfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfsdIR{UUN3ME2yMlAyOjV{IN88US=>NGK0S5RUSU6JRWK=
EW-18MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTJwMEKzN|ch|ryPMmH5V2FPT0WU
DJM-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jTNGlEPTB;Mj6wNlU2OiEQvF2=MlvpV2FPT0WU
no-11NH7FRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIj2O|lKSzVyPUKuNFMyODRizszNM3fWXXNCVkeHUh?=
QIMR-WILNGHUfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jWT2lEPTB;Mj6xOlc3OiEQvF2=MkjsV2FPT0WU
MC-CARM2jKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWmwPIJ7UUN3ME2yMlIzQTVizszNNVzaUYFFW0GQR1XS
KM-H2MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PndmlEPTB;Mj6yPVA1OyEQvF2=NWDSRXY3W0GQR1XS
ECC12NXP2PVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfUTWM2OD1{LkO3PVQh|ryPMYfTRW5ITVJ?
HCE-TMkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzTNmN{UUN3ME2yMlQ1QDh|IN88US=>NFixfoZUSU6JRWK=
MFM-223NYPsPWFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnizTWM2OD1{LkWwPFcyKM7:TR?=M2nx[3NCVkeHUh?=
SW982MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlH6TWM2OD1{LkWxOFgh|ryPMXHTRW5ITVJ?
KG-1MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHuxeY5KSzVyPUKuPFg4QTFizszNM2Py[XNCVkeHUh?=
ES4M3zRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTkTWM2OD1|LkC2NVEyKM7:TR?=NVnMOYliW0GQR1XS
SCC-3NVjZU3d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHodog1UUN3ME2zMlExQDR6IN88US=>MYPTRW5ITVJ?
RH-1NIDtcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjDTWM2OD1|LkO4O|Q5KM7:TR?=NV;JNG5WW0GQR1XS
NCI-H748MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nKPGlEPTB;Mz60OFI3PiEQvF2=NWHSdHEyW0GQR1XS
HCC2218NHrSdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTNwNE[5N|ch|ryPMXvTRW5ITVJ?
MEG-01MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HKWmlEPTB;Mz61PVY5KM7:TR?=MWLTRW5ITVJ?
NB12Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3kSm5KSzVyPUOuOVk5QDhizszNMnHSV2FPT0WU
SNB75NVzEbotlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnRfJRKSzVyPUOuOlAyODNizszNNX\ZR5d[W0GQR1XS
KMS-12-PEMnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTKTWM2OD1|Lk[3O|I{KM7:TR?=M4P6TXNCVkeHUh?=
SKM-1NGXBc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVToeINLUUN3ME2zMlcyOzd4IN88US=>MkfUV2FPT0WU
COLO-320-HSRMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTNwN{W2N|Qh|ryPMVTTRW5ITVJ?
NKM-1NYjifGJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDnTWM2OD1|Lke3N|c5KM7:TR?=M13PXHNCVkeHUh?=
TE-6MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTNwOUS1OlEh|ryPNFG2XmJUSU6JRWK=
D-336MGM2CxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF:0dG5KSzVyPUSuNFEyPjZizszNNF3LTnJUSU6JRWK=
NCI-H1650NWnrNo5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7QTWM2OD12LkG1O|k4KM7:TR?=M4LBT3NCVkeHUh?=
ES3MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvTWnkxUUN3ME20MlMzQDJ2IN88US=>M4HCTHNCVkeHUh?=
YTNXfOd486T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLHbWRUUUN3ME20MlM2PDJ2IN88US=>NGi2clNUSU6JRWK=
ES5NITpWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3JTWM2OD12LkSwNlU2KM7:TR?=MlvuV2FPT0WU
LB647-SCLCNH;EeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3pTWM2OD12LkW2N|A5KM7:TR?=NWHH[ldvW0GQR1XS
HAL-01NVrzR41tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHvdXQ6UUN3ME20MlU4ODN2IN88US=>NInjXlRUSU6JRWK=
LP-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DsemlEPTB;ND63NlM4OSEQvF2=NE[xZ3pUSU6JRWK=
BC-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;WRphKSzVyPUWuNFA1PDdizszNNHjXXndUSU6JRWK=
EB-3Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofZTWM2OD13LkCzNFQyKM7:TR?=NInFbIRUSU6JRWK=
GT3TKBMkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTVwMUe2OlIh|ryPMW\TRW5ITVJ?
NCI-H209MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HrTmlEPTB;NT6xPVM2OiEQvF2=NWjFV4g3W0GQR1XS
BT-474M3jRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXSwbZNQUUN3ME21MlI{OTB{IN88US=>NX7wPWduW0GQR1XS
RKOMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1P4TGlEPTB;NT6yN|QzOiEQvF2=NV23Oo5MW0GQR1XS
SIMAMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHXe49KSzVyPUWuN|A4PjVizszNMnXBV2FPT0WU
RLNFrmUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHuUGJKSzVyPUWuN|c2PDFizszNMmfKV2FPT0WU
GCIYMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTVwNEeyN|Yh|ryPMXLTRW5ITVJ?
Calu-6NWPPVZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDVTWM2OD13Lk[yNkDPxE1?MoPNV2FPT0WU
ALL-PONIH6OolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTPTWM2OD13Lk[zO|k2KM7:TR?=NEDSZ5pUSU6JRWK=
ARH-77NIHXRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mli1TWM2OD13Lk[3NFg4KM7:TR?=M2DJXXNCVkeHUh?=
A4-FukMkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHBOJk3UUN3ME22MlA5OTF6IN88US=>M1TlbXNCVkeHUh?=
NCI-H1581Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1P0bGlEPTB;Nj6yN|g1QSEQvF2=MYnTRW5ITVJ?
HUTU-80NEn0OYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4ewU2lEPTB;Nj6zOlg6PyEQvF2=M{HUdnNCVkeHUh?=
TGWNIHy[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTZwNEW1PVMh|ryPNWPSeoxIW0GQR1XS
SK-N-FINXTqWY9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{GzfmlEPTB;Nj60OVg2PCEQvF2=NWrqSmNGW0GQR1XS
U-266NXPKR2lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTZwNUG5NlYh|ryPNIDtepZUSU6JRWK=
EM-2NHrwNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnX2TWM2OD14Lk[3NFk6KM7:TR?=MlnOV2FPT0WU
NMC-G1M4[0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DzOWlEPTB;Nj63NVg6PSEQvF2=NHfHcG9USU6JRWK=
KASUMI-1M3TMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHoTWM2OD14Lki0O|g4KM7:TR?=NF65OpVUSU6JRWK=
NALM-6MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjNR5F3UUN3ME22Mlg3PzV2IN88US=>MmjRV2FPT0WU
OCI-AML2MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DlbWlEPTB;Nz6wNFMzPiEQvF2=M3vLZ3NCVkeHUh?=
SHP-77NEnWdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PUS2lEPTB;Nz6yNlQ{KM7:TR?=Mnn1V2FPT0WU
NOMO-1NX;KeG1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTdwMkSyOVQh|ryPM{jXUnNCVkeHUh?=
SK-N-DZM3LYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDPNW9KSzVyPUeuO|ExQDlizszNNIGyVZdUSU6JRWK=
LB1047-RCCNF7IdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTdwN{KyN|Eh|ryPM3nRSXNCVkeHUh?=
MZ1-PCMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGOweGtKSzVyPUeuPFY2PThizszNNFq4OWJUSU6JRWK=
NB10M3K0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEf4fXFKSzVyPUeuPVk2PTZizszNNES2So9USU6JRWK=
RL95-2MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HSOWlEPTB;OD6xNFg1OiEQvF2=NEPqTFVUSU6JRWK=
OMC-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml6xTWM2OD16LkWyNVkyKM7:TR?=NWO5VHViW0GQR1XS
D-283MEDNXG1ZndmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRThwOUG3NVkh|ryPMWXTRW5ITVJ?
MC116NW\i[VdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXL4Z4tvUUN3ME24Mlk4QTRizszNMmLMV2FPT0WU
SJSA-1NFvTfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mom3TWM2OD17LkC5NFkyKM7:TR?=NYf2S4p[W0GQR1XS
JiyoyeP-2003MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPiXoo2UUN3ME25MlI6OzF5IN88US=>NW\sUGxtW0GQR1XS
IST-MEL1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHlPWFKSzVyPUmuO|QyQThizszNMm\0V2FPT0WU
CTV-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIW4RWFKSzVyPUGwMlA6PzlizszNNX7tWFdiW0GQR1XS
NH-12M17SVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTFyLkK0N|Mh|ryPMYDTRW5ITVJ?
CA46NX74cGRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTFyLkO2NUDPxE1?NHfzNnZUSU6JRWK=
NCI-SNU-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTFyLkS5Olkh|ryPM1niN3NCVkeHUh?=
SCLC-21HMoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHFPXl5UUN3ME2xNE43PTl4IN88US=>MlvZV2FPT0WU
EC-GI-10NEfMPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTFyLkewN|Eh|ryPMYfTRW5ITVJ?
SRM4nPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXQZpBKSzVyPUGxMlAyQDVizszNNWrrNmdqW0GQR1XS
NCI-H1648MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTFzLkC5OlUh|ryPM171VnNCVkeHUh?=
TGBC1TKBMm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;rTWM2OD1zMT60NVAzKM7:TR?=M1;NeXNCVkeHUh?=
EW-11MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTFzLkWxPFYh|ryPMkL2V2FPT0WU
SK-MM-2MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\hO4RKSzVyPUGxMlgxPjFizszNNW\PfYF2W0GQR1XS
NCI-H524Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjrNlNCUUN3ME2xNU46QDJ{IN88US=>M2C5fXNCVkeHUh?=
NOS-1MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF24NJFKSzVyPUGyMlA{PDVizszNMknsV2FPT0WU
AM-38Mo\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYr4[GVmUUN3ME2xNk42PjN|IN88US=>NX;P[|ZXW0GQR1XS
A498M33vRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1i3UWlEPTB;MUKuO|A3QSEQvF2=NWjJ[JJCW0GQR1XS
KARPAS-422MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XOZmlEPTB;MUKuO|Q6PiEQvF2=M2HafnNCVkeHUh?=
LU-139MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTF{LkmwNlYh|ryPMYfTRW5ITVJ?
COR-L88NVrn[lVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLqTWM2OD1zMj65N|gzKM7:TR?=MoDkV2FPT0WU
K5MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTF{Lkm0OlIh|ryPMmTkV2FPT0WU
NB13MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHHTYFKSzVyPUGyMlk4QDNizszNNXrGOZduW0GQR1XS
MRK-nu-1Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrIWoZKSzVyPUGzMlE6PSEQvF2=NIm0V3NUSU6JRWK=
MHH-NB-11MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXtXnFKSzVyPUGzMlI6ODJizszNM4rpcnNCVkeHUh?=
KU812NY\zOWtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\vfYNKSzVyPUGzMlYyOjRizszNMYHTRW5ITVJ?
TE-12NULBbms6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTF|Lk[5PVQh|ryPM17QWXNCVkeHUh?=
NCI-N87M3zIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTF|LkezOkDPxE1?NXLCWI1mW0GQR1XS
EB2NFPDdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTF|Lki1NFUh|ryPNXjjNFVPW0GQR1XS
DBMlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTF|Lkm4PFUh|ryPNETkOmNUSU6JRWK=
697NHrRdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjCTWM2OD1zND60OVEyKM7:TR?=MmHLV2FPT0WU
MSTO-211HNXPlTGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M324WWlEPTB;MUSuO|Q1QCEQvF2=MmX0V2FPT0WU
JVM-2MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzXWHlKSzVyPUG0Mlc4OzVizszNNIryNYJUSU6JRWK=
COLO-824NXSzUmFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jKXGlEPTB;MUSuO|k6PCEQvF2=NIXLUHhUSU6JRWK=
BC-3MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYH6PItxUUN3ME2xOU4{QThizszNMoTJV2FPT0WU
BOKUMm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX6wOGp2UUN3ME2xOU46PjB6IN88US=>MYHTRW5ITVJ?
GOTOMnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXQSphKSzVyPUG2Mlk3OTdizszNMmDTV2FPT0WU
HCC2157Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTF5LkS3OVUh|ryPNUPrWI9IW0GQR1XS
LS-1034NWDZfpN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HSOmlEPTB;MUeuOlgyQCEQvF2=MWLTRW5ITVJ?
CAL-148MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjLUYRlUUN3ME2xO{46Pzl4IN88US=>MUfTRW5ITVJ?
MOLT-4MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrSXYtkUUN3ME2xPE45OjB6IN88US=>M4ewUHNCVkeHUh?=
DaudiMnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPjdplOUUN3ME2xPE46OjNzIN88US=>MXnTRW5ITVJ?
J-RT3-T3-5Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\aNoRLUUN3ME2xPU41ODZ4IN88US=>M2f1b3NCVkeHUh?=
KMOE-2MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTF7Lk[0PFIh|ryPMm\NV2FPT0WU
HL-60NVvHTGN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTJyLkG5OlUh|ryPM33wPHNCVkeHUh?=
P31-FUJMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mom4TWM2OD1{MD60O|U{KM7:TR?=MUjTRW5ITVJ?
IM-9NWXvPHdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfTWIh5UUN3ME2yNE43OjJ2IN88US=>M4H3dnNCVkeHUh?=
HDLM-2NWDQcIpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG[2WI9KSzVyPUKwMlg5OjFizszNMnnZV2FPT0WU
NCI-H1304NIf2ZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTJzLkCzNVEh|ryPNHy4XWRUSU6JRWK=
NCI-H345M4fKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTJzLkC2OFMh|ryPMV3TRW5ITVJ?
RPMI-6666NWnDeIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PycmlEPTB;MkGuN|YxOiEQvF2=Mm\rV2FPT0WU
GR-STNXTadZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTJzLkSxO{DPxE1?MlPUV2FPT0WU
CHP-126MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjyOlJYUUN3ME2yNU43OThzIN88US=>MWDTRW5ITVJ?
EHEBMkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrUXZFwUUN3ME2yNU43PzNzIN88US=>NGTEVFlUSU6JRWK=
CPC-NNIDyR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;S[2lEPTB;MkSuNFIxOSEQvF2=M3;DfnNCVkeHUh?=
NB1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1n1VWlEPTB;MkSuOlk{QSEQvF2=NGftSodUSU6JRWK=
LS-123MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTJ2LkmwNVIh|ryPNGe3XWpUSU6JRWK=
ST486MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nEW2lEPTB;MkWuNVEyOyEQvF2=MWPTRW5ITVJ?
NCI-H1963M3PKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTrTWM2OD1{Nj6wOlI{KM7:TR?=M1jZdnNCVkeHUh?=
U-87-MGNHS4dXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LYN2lEPTB;Mk[uO|Y1PCEQvF2=MlHpV2FPT0WU
COR-L279MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4frWmlEPTB;Mk[uO|kzOiEQvF2=NH:1fVFUSU6JRWK=
LU-165M4jHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU[1fVhZUUN3ME2yPE4xQDZzIN88US=>NIfnZnFUSU6JRWK=
COLO-800NVnYU5l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3DUJlKSzVyPUK4MlI6PTZizszNNV:zcG5QW0GQR1XS
ETK-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjiTWM2OD1{OD6zOFQ3KM7:TR?=MmLUV2FPT0WU
LNCaP-Clone-FGCM4qwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXoTWM2OD1{OT65NlgyKM7:TR?=MkW3V2FPT0WU
SIG-M5MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjzOYNKSzVyPUOwMlc6PTJizszNM3XNVnNCVkeHUh?=
NB6NUTkRnJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTsS|hKSzVyPUOwMlk2ODNizszNMYfTRW5ITVJ?
NCI-H2107MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jZXWlEPTB;M{GuNlM{QCEQvF2=M1nndHNCVkeHUh?=
SNU-C1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzkTHNTUUN3ME2zNU4{OTJ4IN88US=>M2D5OHNCVkeHUh?=
JARNUDHb5ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\UTWM2OD1|MT6zO|k6KM7:TR?=NIeybmtUSU6JRWK=
L-363MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfr[XBKSzVyPUOyMlIyPDRizszNMlTNV2FPT0WU
EW-24MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPhTWM2OD1|Mj6zOFc1KM7:TR?=NGP1cIFUSU6JRWK=
NB69NVn0c|lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTN|Lk[0OVQh|ryPMlf3V2FPT0WU
EW-13NWrlWItIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX:2Z|RPUUN3ME2zN{45QTZ7IN88US=>MXTTRW5ITVJ?
Ramos-2G6-4C10M4TFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfJNmhKSzVyPUO0MlI6QTNizszNMWDTRW5ITVJ?
TE-11M3m5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTN2LkS4NlIh|ryPM3H5dHNCVkeHUh?=
L-428NIXyfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{X1NGlEPTB;M{SuO|U{PiEQvF2=MVPTRW5ITVJ?
KP-N-YNMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTN2LkmwOVch|ryPM2HSe3NCVkeHUh?=
CGTH-W-1M4PTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknCTWM2OD1|Nj65NFQ5KM7:TR?=MXPTRW5ITVJ?
K-562Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2X5U2lEPTB;M{euNFg3PCEQvF2=NVfwZpVOW0GQR1XS
NCI-H1299M{LIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTrenpuUUN3ME2zPE4yPjB|IN88US=>MVrTRW5ITVJ?
RCC10RGBMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3uz[mlEPTB;M{iuNlA5OyEQvF2=MXvTRW5ITVJ?
NCI-SNU-16MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlj6TWM2OD1|OD61OlU{KM7:TR?=MX\TRW5ITVJ?
LC-2-adMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTN7LkSzN|ch|ryPMWLTRW5ITVJ?
MHH-PREB-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDQTWM2OD1|OT63N|g5KM7:TR?=M{W5UnNCVkeHUh?=
NCI-H64NWHVVYt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfudo1MUUN3ME20NE4xQTR6IN88US=>NIjIVlRUSU6JRWK=
LB996-RCCM{TOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnmTWM2OD12MD64O|E3KM7:TR?=NFjZdpJUSU6JRWK=
DELM{jWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnxTpJKSzVyPUSxMlQ1ODVizszNMVzTRW5ITVJ?
MLMAM2j4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3ruXWlEPTB;NEGuO|U6PSEQvF2=M4TzXXNCVkeHUh?=
SBC-1MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTR{LkG4NFYh|ryPM2rIVXNCVkeHUh?=
MPP-89Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\NTWM2OD12Mj61PFc2KM7:TR?=NFrQfG1USU6JRWK=
MV-4-11M{DxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHsTWM2OD12Mj65NFY4KM7:TR?=NGjhTWRUSU6JRWK=
EoL-1-NELHZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXzTWM2OD12ND6xOVY5KM7:TR?=MmnvV2FPT0WU
CW-2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWT4[HRiUUN3ME20OE45OzR{IN88US=>M3zNdHNCVkeHUh?=
HTM{PMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\yTWM2OD12NT63NFA4KM7:TR?=M1PUOnNCVkeHUh?=
SW954MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjXTWM2OD12Nz60NVI5KM7:TR?=NEfxVVNUSU6JRWK=
A3-KAWNF7PUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nmdGlEPTB;NEmuPFA3OSEQvF2=MnPFV2FPT0WU
TC-YIKNF\NSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nxZmlEPTB;NUCuNFM3OyEQvF2=M4PZUHNCVkeHUh?=
SW962MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfYZlFTUUN3ME21OE45OzV5IN88US=>Ml3PV2FPT0WU
KP-N-RT-BM-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTV4Lk[2N|gh|ryPNX\qZW1IW0GQR1XS
NCI-H1395MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXRdIFyUUN3ME21PE45OTd{IN88US=>NWH0epZuW0GQR1XS
RPMI-8402M{DXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PxNGlEPTB;NUiuPVUzPiEQvF2=M{WzU3NCVkeHUh?=
SCHM33UcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Moj1TWM2OD14MD65OlM5KM7:TR?=NIXCelZUSU6JRWK=
NCI-H2196NIPCUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTZzLkKzNUDPxE1?M1vEd3NCVkeHUh?=
LOXIMVIMof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\K[2pxUUN3ME22NU45OjZ4IN88US=>M3mx[nNCVkeHUh?=
TGBC24TKBMkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPmNVdIUUN3ME22Nk4yPDlzIN88US=>NEOxWXpUSU6JRWK=
SK-MEL-2M37CPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LseWlEPTB;NkOuPVg6OiEQvF2=MmDzV2FPT0WU
U-698-MNWnaeGFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTZ6LkW2PFch|ryPNE\ZXW5USU6JRWK=
NCI-H1522NWi0Oph[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkCxTWM2OD14OT6wNFQ4KM7:TR?=NXnYeWc{W0GQR1XS
UACC-812M4flXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlX2TWM2OD14OT61NlA6KM7:TR?=MV;TRW5ITVJ?
MHH-CALL-2MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLESXVKSzVyPUewMlA3KM7:TR?=MWXTRW5ITVJ?
NB5MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILh[4VKSzVyPUewMlM1PjhizszNM1WxUXNCVkeHUh?=
KARPAS-299M1W4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13UU2lEPTB;N{CuOFQ1PyEQvF2=NILxZ|FUSU6JRWK=
NCI-H1694MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;WTWM2OD15MT6wN|Ih|ryPM1nPTHNCVkeHUh?=
NCI-H82MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\BfGlEPTB;N{GuPVUxPyEQvF2=M4\4dHNCVkeHUh?=
SCC-15NVXTOZVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTd{LkO0JO69VQ>?MYXTRW5ITVJ?
NCI-H1436NYDoR2tWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTd{Lke0OVYh|ryPMX7TRW5ITVJ?
ATN-1M4fOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzZW4lKSzVyPUe0MlUxPSEQvF2=NI\Ud4VUSU6JRWK=
RPMI-8866MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETLeVFKSzVyPUe0Mlc2ODlizszNMmXCV2FPT0WU
HCC1599MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUn5cmJVUUN3ME23OE45PzN{IN88US=>NYrydo4{W0GQR1XS
NCI-H1155MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTd2LkmzOlch|ryPNUKwZXVbW0GQR1XS
DOHH-2NGT3cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTd2Lkm1NVQh|ryPNXLueHl3W0GQR1XS
SK-NEP-1NGKyTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4P3[GlEPTB;N{WuNFc2PCEQvF2=MlH3V2FPT0WU
HCC1187NFfx[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTd5Lk[xNlIh|ryPNELZOY1USU6JRWK=
NCI-H322MNUT6fXNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIC5TXlKSzVyPUe4MlM4ODlizszNM162bHNCVkeHUh?=
NCI-H526NVH1N4tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\5XWlEPTB;N{iuOVg4PyEQvF2=NVPKZpdzW0GQR1XS
NCI-H2171MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;jOWtLUUN3ME23PU41OTN4IN88US=>MoXYV2FPT0WU
COLO-668Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm[2TWM2OD16MT61PFg1KM7:TR?=M2HyOXNCVkeHUh?=
RS4-11NF3rd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkOyTWM2OD16Mj6yOVA2KM7:TR?=M3[w[nNCVkeHUh?=
NCI-H716NXWzfHpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTPTWM2OD16Mj65NFc2KM7:TR?=NXP3dVRzW0GQR1XS
LU-134-ANXq0VXY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33reWlEPTB;OEOuNVM2OSEQvF2=NVLscmdwW0GQR1XS
RPMI-8226NEC4[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;OdZB2UUN3ME24OE4zOTB5IN88US=>NGDsbHRUSU6JRWK=
KY821M3v3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTlzLk[1OVEh|ryPMkDtV2FPT0WU
ECC4M1fhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTvelQ6UUN3ME25N{45OjZ7IN88US=>NXToR4ppW0GQR1XS
EW-3MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\aUmlEPTB;OUSuPVA5OSEQvF2=MoDUV2FPT0WU
NB7MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjnWZVVUUN3ME25OU44Pzh4IN88US=>NH;EVXlUSU6JRWK=
NCI-H720NWHoc5R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljrTWM2OD17OD60NFYyKM7:TR?=MmLVV2FPT0WU
NCI-H446MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zXemlEPTB;OUmuO|U5QCEQvF2=MXnTRW5ITVJ?
NCI-H889MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrJU|BKSzVyPUGwOE4zPDJizszNNGTPdYZUSU6JRWK=
EW-22MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTFyNj6xPUDPxE1?MmnDV2FPT0WU
BV-173M3X1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzJc4t[UUN3ME2xNFgvPzJ6IN88US=>MVnTRW5ITVJ?
WSU-NHLMlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrFeWtlUUN3ME2xNFkvPjdzIN88US=>NE\HTlhUSU6JRWK=
MN-60NIGzfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zyS2lEPTB;MUC5MlY6KM7:TR?=NIfsOoxUSU6JRWK=
DG-75NWrteo5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjBTWM2OD1zMUOuN|UzKM7:TR?=NX2yR5c2W0GQR1XS
DMS-79MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTFzNz6zPFIh|ryPNIPmbFhUSU6JRWK=
SK-MEL-1Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlL6TWM2OD1zMUiuNFA6KM7:TR?=NHK5XolUSU6JRWK=
DMS-153NUfGbmNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;6TWM2OD1zMkGuO|Q2KM7:TR?=NEnCeoNUSU6JRWK=
NCI-H510AM4PQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlixTWM2OD1zMkeuN|Ih|ryPMlXTV2FPT0WU
BE-13MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HqXmlEPTB;MUO0MlA1PCEQvF2=NVzVSI5[W0GQR1XS
KP-N-YSM3KxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\kN|lHUUN3ME2xN|kvPzN4IN88US=>M4rRbHNCVkeHUh?=
SUP-T1NEL2bWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTZTWM2OD1zNEOuO|A5KM7:TR?=MX7TRW5ITVJ?
EW-12MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LFdWlEPTB;MUS0MlY6QSEQvF2=Ml\FV2FPT0WU
NB14NF3hVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTF2Nz6wPFIh|ryPNYrjVIFKW0GQR1XS
MDA-MB-134-VINXjtflBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWf2cmtrUUN3ME2xOFgvOjZ6IN88US=>MVLTRW5ITVJ?
NCI-H1770NIjm[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;P[2lEPTB;MUW2MlI4QSEQvF2=M3j1R3NCVkeHUh?=
TURMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jrUWlEPTB;MU[3Mlg4KM7:TR?=NWrVZ5RqW0GQR1XS
NCI-H1417M2nCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTF6MD6zN|Eh|ryPNUXsSmdyW0GQR1XS
IMR-5NGHUe5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnJe2tPUUN3ME2xPFEvPTdzIN88US=>M3G3bHNCVkeHUh?=
NCI-H226MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rTcmlEPTB;MUi4Mlg3PiEQvF2=NUT1SGRQW0GQR1XS
NCI-H187NUPOXI85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4myVGlEPTB;MUmwMlA3PCEQvF2=MUnTRW5ITVJ?
SF539M1zEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPIdoRKSzVyPUG5Nk44OjhizszNNYiwPZNSW0GQR1XS
TALL-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjNepVMUUN3ME2xPVgvOzB2IN88US=>M3PEVXNCVkeHUh?=
TE-441-TM3fKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTF7OT63N|kh|ryPNFLZZm9USU6JRWK=
REHMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M322d2lEPTB;MkO2MlYzPiEQvF2=NYCzSJlWW0GQR1XS
MS-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknnTWM2OD1{M{muNVIyKM7:TR?=NVzLZodxW0GQR1XS
THP-1NI\BbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTJ4ND63N|gh|ryPNGLvcIhUSU6JRWK=
NCI-H1838NVi4d2NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWSyc5YxUUN3ME2yO|EvPDV4IN88US=>MVnTRW5ITVJ?
P30-OHKNWPmPGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjIU4FKSzVyPUK4N{45PDdizszNM{DYSXNCVkeHUh?=
C8166M1rQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF:3ZmtKSzVyPUO0OU4{OzhizszNM3y1[XNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Measurement of inhibitory activities of MG-132 against 20S proteasome The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.

Cell Assay:

[3]

Cell lines KIM-2, HC11, and ES
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 24, and 48 hours
Method

Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.

Animal Study:

[7]

Animal Models Male mdx (C57BL/10ScSn DMD mdx) mice
Formulation Dissolved in DMSO, and diluted in PBS
Dosages ~10 μg/kg/day
Administration Injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tsubuki S, et al. J Biochem, 1996, 119(3), 572-576.

[2] Fiedler MA, et al. Am J Respir Cell Mol Biol, 1998, 19(2), 259-268.

view more

Chemical Information

Download MG-132 SDF
Molecular Weight (MW) 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 95 mg/mL (199.73 mM)
Ethanol 95 mg/mL (199.73 mM)
Water <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80, pH 4 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name benzyl (S)-4-methyl-1-((S)-4-methyl-1-((S)-4-methyl-1-oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbamate

Customer Product Validation (9)


Click to enlarge
Rating
Source Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck
Method Immunoprecipitation
Cell Lines MDA-MB-231 cells
Concentrations 10 uM
Incubation Time 6 h
Results SIAH2 destabilizes LATS2 through proteasome. SIAH2-mediated LATS2 degradation was inhibited by proteasomal inhibitor MG132, but not by lysosomal inhibitor BA-1. The half-life of LATS2 was shortened by SIAH2.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Western blot
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results As RMND5A downregulation resulted in a rapid decrease of protein Exportin-5, this effect was partially abolished by the proteasome inhibitor MG132, indicating that RMND5A protect Exportin-5 protein against proteasome degradation.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck
Method Immunocytochemistry
Cell Lines HeLa cells
Concentrations 20 uM
Incubation Time 8 h
Results It was surprised to observe that Exportin-5 retention in nucleus when its protein levels were downregulated by RMND5A siRNA or miR-138. The proteasome inhibitor MG132 could recover not only Exportin-5 protein levels but also its normal subcellular localization.

Click to enlarge
Rating
Source EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck
Method Western Blot
Cell Lines MEF cells
Concentrations 30 uM
Incubation Time 6 h
Results Treatment of MEF with proteasome inhibitor MG132 resulted in similar increase of steady state levels of intracellular ATZ in both GFP- and TFEB- transfected Cells.

Click to enlarge
Rating
Source Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck
Method Western Blot
Cell Lines A375, Lu1205 cells
Concentrations 5 uM
Incubation Time 10 h
Results MG132 treatment increased JAK1 steady-state levels, masking the effect of RNF125 depletion and partially blocking deregulated JAK1 expression by ectopically expressed RNF125.

Click to enlarge
Rating
Source Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck
Method Immunoblot analysis
Cell Lines Arabidopsis thaliana
Concentrations 100 uM
Incubation Time 12 h
Results These rates of loss were markedly slower in the lrb1-1 lrb2-1 background. Importantly, phyB breakdown was also substantially attenuated upon exposing wild-type seedlings to the proteasome inhibitor MG132, thus implicating the 26S proteasome in particular. MG132 treatment also slightly stabilized phyB levels in lrb1-1 lrb2-1 seedlings, implying that other factors besides LRB1 and LRB2 might also direct phyB breakdown.

Click to enlarge
Rating
Source Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck
Method Immunofluorescence
Cell Lines γ-H2AX-stained cells
Concentrations 100 uM
Incubation Time 3 h
Results G2 cell cycle arrest usually reflects the formation of genomic damage in the preceding S-phase, which activates checkpoint response upon the entry of cells into G2 phase. Furthermore, MG132-treated cells also had larger amounts of γ-H2AX, as evidenced by the increased staining in individual nuclei .

Click to enlarge
Rating
Source FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck
Method Western Blot
Cell Lines Hela cells
Concentrations
Incubation Time 12 h
Results When GSK-3 (Ser9) degradation was blocked by proteasome inhibitor (MG132), the increased amount of phosphorylated GSK-3 (Ser9) in responding to NOK was more clearly observed in the HeLa-NOK-HA cells (Fig. C).

Click to enlarge
Rating
Source 2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck
Method Western blot
Cell Lines NIH3T3 cells
Concentrations 25 μM
Incubation Time 1-4 h
Results By adding MG132, a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment.

Product Use Citation (42)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • Bortezomib (PS-341)

    Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us